The story appears on

Page A4

April 20, 2021

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » Metro

Local doctors develop novel lung cancer therapy

Local medical experts have developed an innovative therapy for terminal-stage lung cancer patients to achieve longer survival rates and better life quality.

It is the world’s first such therapy combining immunotherapy and targeted drugs that inhibit the formation of new blood vessels in tumors, creating a new approach to non-chemotherapy treatments, medical experts from Shanghai Chest Hospital said yesterday.

The traditional treatment for patients in late stages of lung cancer is chemotherapy or a combination of chemotherapy and immunotherapy. However, the survival and cancer-control rates are not high. The average survival time without cancer reemerging for patients with chemotherapy is only 4 months and 7-9 months for those who receive chemotherapy and immunotherapy — but chemotherapy has serious side effects.

“Since I was in charge of the domestic development of the new drug that inhibits new blood vessels from forming, we have been working on new treatments that bring more benefits to patients while avoiding the adverse side effects of chemotherapy,” said Dr Han Baohui of the hospital. “We chose two domestic medications with good results to offer a new solution to patients.”

During the first round of clinical trials in late 2018, all 22 participants reported their tumors were under control, including 72.7 percent where the cancer was reduced by at least 30 percent. The average survival rate without cancer reemergence was 15 months, and 95.5 percent of patients have survived for at least 12 months. “The safety of the treatment has been confirmed, and it’s expected to improve the survival rates and quality of life for terminal lung cancer patients,” Han noted.


Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend